Raymond James expects modest upside for this MedTech stock in Q3 results
Raymond James sees scope for modest upside when a major medical technology (MedTech) group reports third-quarter earnings, pointing to steady ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
